Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Time to Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s share price gapped up prior to trading on Friday . The stock had previously closed at $60.06, but opened at $61.95. Prestige Consumer Healthcare shares last traded at $61.4020, with a volume of 168,459 shares trading hands.

Wall Street Analyst Weigh In

PBH has been the subject of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Jefferies Financial Group lowered their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $76.50.

Prestige Consumer Healthcare Price Performance

The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The company has a market cap of $2.89 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 1.92 and a beta of 0.41. The stock’s 50-day simple moving average is $65.82 and its 200 day simple moving average is $63.29.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. Prestige Consumer Healthcare’s revenue was down 2.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after buying an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,289 shares during the period. Goldman Sachs Group Inc. grew its position in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Jane Street Group LLC grew its position in Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).